Menu
Not yet recruiting NCT06527040

Clinical Decision Support for Safety of Opioid Transitions

Observational Medication Abuse Harm Reduction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Opioid Transitions Clinical Decision Support (CDS).
Who it may be relevant to
Registry conditions: Medication Abuse, Harm Reduction. Basic parameters: 12 years — 89 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The objective of this study is to evaluate the impact of clinical decision support (CDS) alert to notify providers when the opioid prescription being written will result in the patient transitioning into a new phase of opioid therapy. The 2022 CDC clinical practice guideline for prescribing opioids for pain recommends providers reassess patient pain as well as the risks and benefits of opioid therapy before patients transition from acute to subacute treatment (1 month of opioid analgesics) and when patients transition from subacute to chronic opioid treatment (3 months). This study will evaluate a clinical decision support tool identifying patients who will be transitioning between phases as a result of an opioid prescription and suggest a review of patient pain and goals. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will not be notified that the prescription transitions the patient to a new phase but will have access to the same patient pain scales and information. The intervention arm will receive a notification of the transition and suggest review of patient needs and encourage documentation. Opioid transition orders and outcomes of patients will be examined based on medical records data collected during routine care.

Interventions

  • Other Opioid Transitions Clinical Decision Support (CDS)
    Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.

Primary outcome measures

  • Percentage of encounters with an opioid transitioning prescription [Time frame: 18 months]
Secondary outcome measures (4)
  • Clinical decision support (CDS) acceptance rate [Time frame: 18 months]
  • Subsequent opioid overdose/poisoning rates [Time frame: Six months after an encounter where the opioid use disorder is identified]
  • Opioid prescription abandonment [Time frame: 18 months]
  • Number of patients with long term opioid use [Time frame: Six months after an encounter where the opioid use disorder is identified]

Eligibility criteria

Inclusion Criteria: Any primary care encounter where an opioid is prescribed that transitions the patient to a different stage of opioid therapy (acute to subacute after 1 month of opioids; subacute to chronic after 3 months of an opioid)

Exclusion criteria

  • Patients <12 and >89
  • Patients with active cancer diagnosis in last 1 year
  • Patients with hospice care/palliative care order
  • Patients with sickle cell disease diagnosis

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06527040 · 24-1192 · R61DA057610

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗